SCHEMBL9915919

SCHEMBL9915919

CN(C)c1ccc(/C=C/c2cc[n+](CC(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 4/20 0.56
KDM2A Q9Y2K7 4/20 0.56
MAPT P10636 5/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
HTT P42858 3/20 0.54
ALDH1A1 P00352 2/20 0.54
CASP1 P29466 2/20 0.54
HBB P68871 2/20 0.54
GAA P10253 1/20 0.54
BRCA1 P38398 1/20 0.54
CASP7 P55210 1/20 0.54
LMNA P02545 1/20 0.54
ALPG P10696 1/20 0.54
THRB P10828 1/20 0.54
GFER P55789 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
RELA Q04206 1/20 0.51
HSD17B3 P37058 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18349216 0.88 KDM4A (0.56) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
SCHEMBL19860017 0.86 MEN1 (0.57) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
SCHEMBL15797226 0.86 KDM4A (0.58) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
SCHEMBL15797224 0.86 KDM4A (0.58) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
Bromide SCHEMBL17221056 0.85 KDM4A (0.57) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
SCHEMBL19519178 0.85 CHRM2 (0.54) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
SCHEMBL19506338 0.85 CHRM2 (0.54) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
Bromide SCHEMBL17221057 0.85 KDM4A (0.57) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL19469279 0.84 CHRM2 (0.53) KDM4AKDM2AMAPTSMN1; SMN2KMT2A
Hydrochloric Acid SCHEMBL19469278 0.84 CHRM2 (0.53) KDM4AKDM2AMAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170953-A1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) 2018-06-21 US disclosed
US-20160376298-A1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) 2016-12-29 US disclosed
US-8723017-B2 Dye sensitised solar cell BASF SE (DE) 2014-05-13 US disclosed
US-8709299-B2 Dye sensitised solar cell BASF SE (DE) 2014-04-29 US disclosed
EP-2253031-B1 DYE SENSITISED SOLAR CELL BASF SE (DE) 2012-10-17 EP disclosed
US-20120145238-A1 DYE SENSITISED SOLAR CELL BASF SE (DE) 2012-06-14 US disclosed
US-20110061723-A1 DYE SENSITISED SOLAR CELL BASF SE (DE) 2011-03-17 US disclosed
WO-2009109499-A1 DYE SENSITISED SOLAR CELL BASF SE (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145238-A1 DYE SENSITISED SOLAR CELL FTO, TET1, METTL14 KDM4A 303/4885KDM2A 394/4885MAPT 1981/4885
US-20110061723-A1 DYE SENSITISED SOLAR CELL FTO, TET1, METTL14 KDM4A 303/4885KDM2A 394/4885MAPT 1981/4885
US-20160376298-A1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER TP53, MKI67, FLT3 KDM4A 1575/4885KDM2A 2114/4885MAPT 4308/4885
US-20180170953-A1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER TP53, MKI67, FLT3 KDM4A 1575/4885KDM2A 2114/4885MAPT 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.